Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more
Crossject (ALCJ) - Total Assets
Latest total assets as of June 2025: €31.38 Million EUR
Based on the latest financial reports, Crossject (ALCJ) holds total assets worth €31.38 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Crossject - Total Assets Trend (2010–2024)
This chart illustrates how Crossject’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Crossject - Asset Composition Analysis
Current Asset Composition (December 2024)
Crossject's total assets of €31.38 Million consist of 50.3% current assets and 49.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.3% |
| Accounts Receivable | €4.29 Million | 13.6% |
| Inventory | €3.42 Million | 10.8% |
| Property, Plant & Equipment | €5.05 Million | 16.0% |
| Intangible Assets | €9.60 Million | 30.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Crossject's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crossject's current assets represent 50.3% of total assets in 2024, a decrease from 60.4% in 2010.
- Cash Position: Cash and equivalents constituted 22.3% of total assets in 2024, up from 10.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 22.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 30.4% of total assets.
Crossject Competitors by Total Assets
Key competitors of Crossject based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Crossject - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Crossject generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Crossject is currently not profitable relative to its asset base.
Crossject - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.70 | 1.71 | 1.81 |
| Quick Ratio | 2.15 | 1.24 | 1.56 |
| Cash Ratio | 0.00 | 0.00 | 0.02 |
| Working Capital | €9.88 Million | € 6.59 Million | € 4.68 Million |
Crossject - Advanced Valuation Insights
This section examines the relationship between Crossject's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 40.53 |
| Latest Market Cap to Assets Ratio | 3.34 |
| Asset Growth Rate (YoY) | 10.2% |
| Total Assets | €31.57 Million |
| Market Capitalization | $105.49 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Crossject's assets at a significant premium ( 3.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Crossject's assets grew by 10.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Crossject (2010–2024)
The table below shows the annual total assets of Crossject from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €31.57 Million | +10.22% |
| 2023-12-31 | €28.64 Million | -12.84% |
| 2022-12-31 | €32.86 Million | +4.23% |
| 2021-12-31 | €31.52 Million | -6.15% |
| 2020-12-31 | €33.59 Million | +37.13% |
| 2019-12-31 | €24.49 Million | +21.51% |
| 2018-12-31 | €20.16 Million | +13.79% |
| 2017-12-31 | €17.72 Million | +24.33% |
| 2016-12-31 | €14.25 Million | +2.67% |
| 2015-12-31 | €13.88 Million | -24.46% |
| 2014-12-31 | €18.37 Million | +225.23% |
| 2013-12-31 | €5.65 Million | +117.87% |
| 2012-12-31 | €2.59 Million | -10.28% |
| 2011-12-31 | €2.89 Million | +8.12% |
| 2010-12-31 | €2.67 Million | -- |